Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
85.92 USD   +4.09%
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
08/04INSIDER SELL : Novocure
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Novocure to Report Second Quarter 2022 Financial Results

07/01/2022 | 08:01am EDT

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss the company’s financial results for the three and six months ended June 30, 2022, at 8 a.m. EDT on Thursday, July 28, 2022. To access the conference call by phone, use the following registration link, and dial-in details will be provided.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website,, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Jersey, and with a growing global footprint, Novocure has regional operating centers in Root, Switzerland, Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 24, 2022 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

© Business Wire 2022
08/10Novocure Hosts U.S. Sen. Maggie Hassan at Company's Portsmouth Facility
08/04INSIDER SELL : Novocure
07/29Truist Securities Drops NovoCure's Price Target to $105 From $118, Keeps Buy Rating
07/29Piper Sandler Adjusts NovoCure's Price Target to $90 From $100, Reiterates Overweight R..
07/28NovoCure Q2 Loss Widens, Net Revenue Rises
07/28TRANSCRIPT : NovoCure Limited, Q2 2022 Earnings Call, Jul 28, 2022
07/28NOVOCURE : Q2 Earnings Snapshot
07/28NOVOCURE : Quarterly net revenues of $140.9 million, a 6% increase year-over-year - Form 8..
07/28Novocure Reports Second Quarter 2022 Financial Results
07/28NOVOCURE LTD Management's Discussion and Analysis of Financial Condition and Results o..
More news
Analyst Recommendations on NOVOCURE LIMITED
More recommendations
Financials (USD)
Sales 2022 547 M - -
Net income 2022 -86,5 M - -
Net Debt 2022 113 M - -
P/E ratio 2022 -110x
Yield 2022 -
Capitalization 8 999 M 8 999 M -
EV / Sales 2022 16,7x
EV / Sales 2023 15,7x
Nbr of Employees 1 167
Free-Float 86,8%
Duration : Period :
NovoCure Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVOCURE LIMITED
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 8
Last Close Price 85,92 $
Average target price 94,25 $
Spread / Average Target 9,70%
EPS Revisions
Managers and Directors
Asaf Danziger Chief Executive Officer & Director
Ashley Cordova Chief Financial Officer
William F. Doyle Executive Chairman
Uri Weinberg Chief Science Officer
Ely Benaim Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PENUMBRA, INC.-40.13%6 435
GETINGE AB-42.75%6 133